Beyond the Genetic Ceiling: How Scholar Rock's FDA Approval for Isembyld Unlocks the Muscle-Directed Neuromuscular Economy
Dr. Dereck Mush, MD, MBA
Scholar Rock
A biopharmaceutical company developing medicines that target growth factors in their local tissue environments.
What they do
Scholar Rock applies its selective myostatin biology platform to neuromuscular diseases, including apitegromab for spinal muscular atrophy.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Neuromuscular and rare diseases
- Product type
- Platform software
- Stage
- Public
- Headquarters
- Cambridge, USA
- Region
- North America
- Founded
- 2012
- Total funding
- Undisclosed
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
A CDMO partnership shows how gene therapy manufacturing is scaling for chronic disease
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
Transporter-Independent Pharmacology and the Orphan PRV Playbook
Dr. Dereck Mush, MD, MBA